Your browser doesn't support javascript.
loading
Diapause-like Drug-Tolerant Persister State: The Key to Nirvana Rebirth.
Chen, Han-Lin; Jin, Wei-Lin.
Afiliação
  • Chen HL; The First Clinical Medical College, Lanzhou University, Lanzhou 730000, China.
  • Jin WL; Institute of Cancer Neuroscience, Medical Frontier Innovation Research Center, The First Hospital of Lanzhou University, Lanzhou 730000, China.
Medicina (Kaunas) ; 60(2)2024 Jan 28.
Article em En | MEDLINE | ID: mdl-38399515
ABSTRACT
Cancer is one of the leading causes of death in the world. Various drugs have been developed to eliminate it but to no avail because a tumor can go into dormancy to avoid therapy. In the past few decades, tumor dormancy has become a popular topic in cancer therapy. Recently, there has been an important breakthrough in the study of tumor dormancy. That is, cancer cells can enter a reversible drug-tolerant persister (DTP) state to avoid therapy, but no exact mechanism has been found. The study of the link between the DTP state and diapause seems to provide an opportunity for a correct understanding of the mechanism of the DTP state. Completely treating cancer and avoiding dormancy by targeting the expression of key genes in diapause are possible. This review delves into the characteristics of the DTP state and its connection with embryonic diapause, and possible treatment strategies are summarized. The authors believe that this review will promote the development of cancer therapy.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Diapausa / Neoplasias Limite: Animals / Humans Idioma: En Revista: Medicina (Kaunas) Assunto da revista: MEDICINA Ano de publicação: 2024 Tipo de documento: Article País de afiliação: China

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Diapausa / Neoplasias Limite: Animals / Humans Idioma: En Revista: Medicina (Kaunas) Assunto da revista: MEDICINA Ano de publicação: 2024 Tipo de documento: Article País de afiliação: China